SEC Investigation Extends Valeant Pharma's (VRX) Road to Confidence - BMO

UPDATE: Canaccord Genuity Downgrades Valeant Pharmaceuticals (VRX) to Hold

(Updated - March 2, 2016 1:08 PM EST)

Canaccord Genuity downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold and lowered its price target to $75 (from $125). Valeant recently confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress.

Analyst Neil Maruoka commented... More

Valeant Pharma (VRX) Pares Earlier Decline

Valeant Pharma (NYSE: VRX) pared earlier declines to trade lower by only 1.3%.

Valeant (VRX) PT Cut to $106 at Jefferies

Jefferies analyst David Steinberg lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $106.00 (from $172.00) while maintaining a Buy rating.

Steinberg commented, "With the return of CEO Mike Pearson, a critical issue has been addressed. However, a host of equally critical questions have... More

Deutsche Bank Suspends Coverage on Valeant Pharma (VRX)

Deutsche Bank suspended its rating on Valeant Pharma (NYSE: VRX). The bank's prior rating was 'Hold'.

Analyst Gregg Gilbert said, "Based on Valeants plans to restate prior results, the delay in filing its 10-K, the removal of prior 16 guidance, and an ongoing Board... More

Valeant Pharma (VRX) Provides Statement on SEC Investigation

Valeant Pharma (NYSE: VRX) said:

"In response to media inquiries, Valeant confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress. With respect to the SEC... More

Mizuho Reiterates Neutral Stance on Valeant (VRX) as Earnings Call Canceled/Guidance Withdrawn -

Valeant Pharmaceuticals (NYSE: VRX) announced that: 1) it is canceling its Feb 29 earnings call (and pulling out of sell-side events); 2) reinstating J. Michael Pearson as its CEO while Howard Schiller transitions to the Board of Directors; and 3) withdrawing its 2016 revenue guidance of $12.5-12.7B.... More

TD Securities Downgrades Valeant Pharmaceuticals (VRX) to Hold

TD Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold with a price target of $110.00 (from $155.00). The change follows news the company has withdrawn guidance.

"We are downgrading Valeant to HOLD from Buy to reflect the reduced visibility into F2016 outlook. The downgrade... More